1. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study
- Author
-
Douglas Girgenti, Joseph M. Severs, Shite Sebastian, Kathrin U. Jansen, James Baber, Jasdeep Singh Nanra, David J. Seiden, Annaliesa S. Anderson, Martin K. Kankam, Robert W. Frenck, Eric Sheldon, William C. Gruber, Robin Hubler, Edward T. Zito, C. Buddy Creech, and Joseph Eiden
- Subjects
Male ,0301 basic medicine ,Staphylococcus aureus ,Drug-Related Side Effects and Adverse Reactions ,Dose-Response Relationship, Immunologic ,Placebo ,medicine.disease_cause ,Placebos ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Bacterial Proteins ,Double-Blind Method ,Phagocytosis ,Antigen ,Immunology and Microbiology(all) ,medicine ,Humans ,030212 general & internal medicine ,Adverse effect ,Aged ,Aged, 80 and over ,Immunoassay ,Antigens, Bacterial ,Vaccines, Synthetic ,General Veterinary ,General Immunology and Microbiology ,biology ,business.industry ,Immunogenicity ,Polysaccharides, Bacterial ,Public Health, Environmental and Occupational Health ,Staphylococcal Vaccines ,Opsonin Proteins ,veterinary(all) ,Antibodies, Bacterial ,Healthy Volunteers ,Vaccination ,030104 developmental biology ,Infectious Diseases ,Immunology ,biology.protein ,Molecular Medicine ,Female ,Antibody ,business - Abstract
Background A prophylactic Staphylococcus aureus four-antigen vaccine (SA4Ag) is under development for prevention of invasive S. aureus disease. A preliminary S. aureus three-antigen vaccine (SA3Ag) was reformulated to include a novel manganese transporter protein (MntC or rP305A). This study describes the first-in-human dose-finding, safety, and immunogenicity results for SA4Ag. Methods In this double-blind, sponsor-unblind, placebo-controlled, phase 1/2 study, 454 healthy adults aged 18–64 years were randomised to receive a single dose of one of three formulations of SA4Ag with escalating dose levels of rP305A or placebo. Functional immune responses were measured using opsonophagocytic activity (OPA) killing and fibrinogen-binding inhibition (FBI) assays; antigen-specific immunogenicity was assessed using a four-plex competitive Luminex® immunoassay (cLIA). Results A high proportion of SA4Ag recipients met the pre-defined antibody thresholds for each antigen at Day 29. A substantial and dose-level dependent immune response was observed for rP305A, with up to 18-fold rises in cLIA titres at Day 29. Robust functional responses were demonstrated, with >80-fold and >20-fold rises in OPA assay titres at Day 29 using S. aureus strains expressing capsular polysaccharide serotypes 5 and 8, respectively. Durable antibody responses were observed through month 12, gradually waning from peak levels achieved by days 11–15. SA4Ag was well tolerated, and no vaccine-related serious adverse events were reported. Conclusions Single-dose vaccination of SA4Ag in healthy adults aged 18–64 years safely induced rapid and robust functional immune responses that were durable through month 12, supporting further development of this vaccine. Trial registration number: NCT01364571
- Published
- 2017
- Full Text
- View/download PDF